 Ayala Pharmaceuticals Inc NASDAQ: AYLA announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrentmetastatic RM adenoid cystic carcinoma ACC harboring Notch-activating mutations. The data was presented at the 2021 ESMO Virtual Congress ESMO21. 